VEGFA and neoplasm: Recently, preclinical and clinical studies regarding the metronomic use of low dose ZOL demonstrated more anti-tumor efficacy than conventional therapy in breast cancer patients in the reduction of biomarkers, such as NTx and VEGF [24].